Repatha Pricing Pressure Might Actually Increase After Outcomes Trial

Amgen's FOURIER study prompts ICER to plan new value-based price benchmark for Repatha below its previously recommended range of $5,404 to $7,735 per year.

Cholesterol plaque in artery

The Institute for Clinical and Economic Review (ICER) is planning to lower its "value-based" pricing benchmark for Amgen Inc.'s Repatha (evolocumab) following the recent release of final results of the FOURIER cardiovascular outcomes trial on the drug.

Announced in mid-March, FOURIER results showed a 15% reduction in a composite of major adverse cardiovascular events in patients with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

More from Market Access

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By 

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

How Could MFN Pricing Impact Commercial Market?

 
• By 

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.